Literature DB >> 1898744

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.

J E Nestler1, L P Powers, D W Matt, K A Steingold, S R Plymate, R S Rittmaster, J N Clore, W G Blackard.   

Abstract

To determine whether hyperinsulinemia can directly reduce serum sex hormone-binding globulin (SHBG) levels in obese women with the polycystic ovary syndrome, six obese women with this disorder were studied. Before study, ovarian steroid production was suppressed in each woman by the administration of 7.5 mg of a long-acting GnRH agonist, leuprolide depot, im, on days -56, -28, and 0. This resulted in substantial reductions in serum concentrations of testosterone (from 1.72 +/- 0.29 nmol/L on day -56 to 0.32 +/- 0.09 nmol/L on day 0), non-SHBG-bound testosterone (from 104 +/- 16 pmol/L on day -56 to 19 +/- 5 pmol/L on day 0), androstenedione (from 7.25 +/- 1.65 nmol/L on day -56 to 2.78 +/- 0.94 nmol/L on day 0), estrone (from 371 +/- 71 pmol/L on day -56 to 156 +/- 29 pmol/L on day 0), estradiol (from 235 +/- 26 pmol/L on day -56 to 90 +/- 24 pmol/L on day 0), and progesterone (from 0.28 +/- 0.12 nmol/L on day -56 to 0.08 +/- 0.02 nmol/L on day 0). Serum SHBG levels, however, did not change (18.8 +/- 2.8 nmol/L on day -56 vs. 17.8 +/- 2.6 nmol/L on day 0). While continuing leuprolide treatment, the women were administered oral diazoxide (300 mg/day) for 10 days to suppress serum insulin levels. Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min.L on day 0 vs. 102 +/- 33 nmol/min.L on day 10; P less than 0.05) and deterioration of glucose tolerance. Serum testosterone, androstenedione, estrone, estradiol, and progesterone levels did not change during combined diazoxide and leuprolide treatment. In contrast, serum SHBG levels rose by 32% from 17.8 +/- 2.6 nmol/L on day 0 to 23.5 +/- 2.0 nmol/L on day 10 (P less than 0.003). Due primarily to the rise in serum SHBG levels, serum non-SHBG-bound testosterone levels fell by 43% from 19 +/- 5 pmol/L on day 0 to 11 +/- 4 pmol/L on day 10 (P = 0.05). These observations suggest that hyperinsulinemia directly reduces serum SHBG levels in obese women with the polycystic ovary syndrome independently of any effect on serum sex steroids.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898744     DOI: 10.1210/jcem-72-1-83

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  125 in total

1.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

2.  Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.

Authors:  Marcus A Rosencrantz; Mickey S Coffler; Annette Haggan; Kimberly B Duke; Michael C Donohue; Rana F Shayya; H Irene Su; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

Review 3.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

4.  Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome.

Authors:  Claudia Gagnon; Jean-Patrice Baillargeon
Journal:  CMAJ       Date:  2007-03-27       Impact factor: 8.262

Review 5.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

6.  Improved responsiveness of PCOS patients to clomiphene after CYP17a inhibitor.

Authors:  H Ali Hassan; D El-Gezeiry; T M Nafaa; I Baghdady
Journal:  J Assist Reprod Genet       Date:  2001-11       Impact factor: 3.412

7.  Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters.

Authors:  L Sieminska; B Marek; B Kos-Kudla; D Niedziolka; D Kajdaniuk; M Nowak; J Glogowska-Szelag
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

8.  Diabetes mellitus and risk of endometrial cancer: a meta-analysis.

Authors:  E Friberg; N Orsini; C S Mantzoros; A Wolk
Journal:  Diabetologia       Date:  2007-05-03       Impact factor: 10.122

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Effects of gastric bypass surgery on female reproductive function.

Authors:  Richard S Legro; William C Dodson; Carol L Gnatuk; Stephanie J Estes; Allen R Kunselman; Juliana W Meadows; James S Kesner; Edward F Krieg; Ann M Rogers; Randy S Haluck; Robert N Cooney
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.